Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Share price vs its Moving Average line...
Just an observation, but have noticed that when a share price gets too far ahead of the moving average line,
they like to get back together. Can either involve the share price falling back & the MA line trying to catch up or the MA line catching up with the share price running flat. Always hope for the latter, but usually get the first especially if the share price got over enthusiastic in its movement (as Jags recently did)..
Now that its in its 4th day of closing prices (includes the day of the 25 cent spike), its within 2 cents of its closing price 4 days ago. Thats not to bad if this price range of 16-18 cents holds for a few more days while the MA line catches up from around 13 cents..
disclaimer: hold some, looking for 25 cents as a first target at the moment based on the news of a potential revenue stream developing. Then there is the PH 3 Wild Card..
You mean, wake up to my free shares lol
hahah so much volume that the borrow rate fee went to N/A 😂
no run coming and if run comes i short the hell out of it
???? wake up bro
Why shorting bro, try buying and enjoy the ride soon, imho all wins
Not sure that would be our definition of idiot!!! Didn’t you say you were in and then got out so if you were in then you bought some right that mean you’re an idiot
That looks awesome
In my opinion at the time p3 results $5 and after the report not need a RS the real run to $100 starts :))
right after big R/S
IMHO it will be a $100 stock
Thanks what I can expect lol…
I'll be wiping my tears with the $100,000 I've already made asshat ;)
how do i know lol
read some fillings
i feel bad for you .... your dd sucks on this company and you will lose your wife money
How do you dilution going on and why anybody shud be here when not interested? Says a lot.. IMHO lots of shorts working hard :))
Honestly I don't feel bad for them, I researched this stock myself almost 2 years ago before even joining this board, and they have been inconsiderate the whole time I've been here. I have no sympathy for a bunch of angry children, just put a binky in their mouth to shut em up :^)
Insiders own 2% of the O/S lol tells the story here !!!!!!!
IF INSIDERS DONT BUY DONT INVEST !!!!!
only idiots invest in this dilution turd
you idiots deserve to lose big time here
bambi jongen anders spel ik wel in het
nederlands, frans of duits maar dat zal je niet begrijpen want jullie spreken enkel engels .
Omhooggevallen idioten.
His spelling is the givway(sic) lol
Just a prelude of what's yet too come.The 5 year licensing agreement adds cash and positions the company for success.Next is the Phase 3 report, which if positive,could send this into the stratosphere.Things are looking up.Good luck and good trading.
whatever little man
Yes I need to grow up when you and your 3 alt accounts come in here bitching and moaning everyday. When in reality you're FUMING with anger because this company is going to be successful.
grow up bro
people losing intrest that all
Lol paid bashers coming out to try and take your shares XD
Same here I gave up this morning on it RS coming for sure kept in and out few times hoping it keeps going up but this one hopeless cash out with small lost
100% Agreeee free ATM
https://www.sharesmagazine.co.uk/news/market/LSE20240419070008_5149779/rcf-in-place-and-new-partner-in-the-usa
The 5 Year Licensing Deal has been finalized :D That is a YUGE indication that JAGX are making long-term partnerships worldwide...
Its the stock market, things go up and down all the time, even when a 'run' is happening..
Should stay focused on the CHART. Cause at the moment, the share price is looking for its Moving Average line.
The share price has gotten ahead of this MA line, and from experience, they don't like to get separated for too long
before they want to get back together again. This happens over and over again..
Now I have to figure out how to post a snapshot of my chart on this forum.. to show you what I mean. Hmmm
59 minutes ago 2024-04-19 09:54:24.314 3,600,000
2 hours ago 2024-04-19 08:49:03.831 2,000,000
4 hours ago 2024-04-19 06:38:04.653 1,900,000
5 hours ago 2024-04-19 05:00:52.462 1,700,000
6 hours ago 2024-04-19 03:56:25.237 1,500,000
8 hours ago 2024-04-19 02:18:06.687 1,400,000
9 hours ago 2024-04-19 01:13:14.507 1,300,000
17 hours ago 2024-04-18 17:51:07.149 2,000,000
18 hours ago 2024-04-18 16:46:37.211 2,100,000
18 hours ago 2024-04-18 16:14:58.499 1,900,000
LOL look at all these returned shares in just the last 24 hours
Never holds a darn gain ...
I got out at .19 a couple days ago , however I do wish everyone holding the Best of Luck , take care !
If your ahead at all in the Stock market or even just a bit in the red , Id pull my money out and be safe for now . In my Opinion the market is fixing to spiral . If you want to stay in you better put into Oil and Gas ! Good Luck regardless your choices !
ENTIRE market is bleeding and jaguar health is about to capture so much marketcap muhahahahaha
LOL hahaha I'd be down to do that, Binance is the biggest bag holder of Shib you know they will want to pump it when BTC hits over $100,000
You don't hire people in top exec positions if you don't have a job for them. What's her job? In-liscensing.
In-licensing refers to the process where a company (the licensee) acquires the rights to a product, technology, or intellectual property from another organization (the licensor). This can include rights to develop, manufacture, and market a particular pharmaceutical product. In-licensing allows the licensee to expand its product portfolio, access innovative technologies, and enter new markets without having to develop the product or technology in-house.
After we take our gains in the double digits, we shall roll them into $SHIB Shiba Inu coin will be the next .01c crypto IMO not financial advice
The PLOS dog study was nonetheless more proof in the pudding. P VALUE WAS FANTASTIC 😊
Significantly more patients receiving crofelemer 125 mg achieved clinical response versus placebo (17.6% vs 8.0%; one-sided, P = .01). Crofelemer 125 mg resulted in a greater change from baseline in number of daily watery bowel movements (P = .04) and daily stool consistency score (P = .02) versus placebo. During the placebo-free extension phase, percentages of weekly responders ranged from 40% to 56% at weeks 11 to 24. Crofelemer was minimally absorbed, well tolerated, did not negatively impact clinical immune parameters, and had a safety profile comparable to placebo.
Conclusions: In HIV-seropositive patients taking stable antiretroviral therapy, crofelemer provided significant improvement in diarrhea with a favorable safety profile.
Lambo not my taste, I'm more of a nismo fan. Gtr all the way.
Don't believe the bears anywhere. Stick to the plan. $1 first, then it's ballgame. The ceiling is currently $9 when this reverse split last that's what it ran too.
In a clinical study known as the ADVENT trial, 374 adults living with HIV on antiretroviral therapy (ART) who had been experiencing noninfectious diarrhea for at least 1 month were given either 125 mg of Mytesi twice a day or a placebo (sugar pill).1 The study looked at how effective treatment was in an ethnically diverse patient population, comprised predominantly of male long-term survivors (LTSs).*
*LTS is a person living with HIV for >10 years.
Can we get matching Lambos John :^)
if my calculations are correct we should be at .75c+ the fact of matter is the dark pool shorts are so fkd it's not even funny. I called my broker buddy today in NY, he ran behind scenes found some shit out for me. The FTDs are going to be so high for April it's not even funny..... The dark pool shorts are trading half the float daily and getting percentages of them stuck in there and they have to long to not lose money. It's coming to the tip of the iceberg. Like if you take a very tiny glass and pour a 5 gallon bucket of water in it. The tiny glass is about to go flying, water everywhere, and everything under water, including the fraudulent brokers allowing it to happen. The stock price might pull a GameStop. Not financial advice. Ph3 data, the orphan drug designation, the other 5 indications, this drug is going to capture billions in marketcap.
Followers
|
148
|
Posters
|
|
Posts (Today)
|
39
|
Posts (Total)
|
5780
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |